A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine in Adult and Elderly Subjects.

Trial Profile

A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine in Adult and Elderly Subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2014

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; Influenza virus vaccine; MF 59
  • Indications Influenza A virus H5N1 subtype; Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 19 Dec 2011 Results published in Vaccine.
    • 07 Jan 2010 Actual patient number (3647) added as reported by ClinicalTrials.gov.
    • 07 Jan 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top